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There is strong evidence that both adoptive T cell transfer and T cell checkpoint blockade can lead to regression of
human melanoma. However, little data are available on the effect of these cancer therapies on the tumor-reactive T cell
compartment. To address this issue we have profiled therapy-induced T cell reactivity against a panel of 145 melanoma-
associated CD8
+ T cell epitopes. Using this approach, we demonstrate that individual tumor-infiltrating lymphocyte cell
products from melanoma patients contain unique patterns of reactivity against shared melanoma-associated antigens,
and that the combined magnitude of these responses is surprisingly low. Importantly, TIL therapy increases the breadth
of the tumor-reactive T cell compartment in vivo, and T cell reactivity observed post-therapy can almost in full be
explained by the reactivity observed within the matched cell product. These results establish the value of high-
throughput monitoring for the analysis of immuno-active therapeutics and suggest that the clinical efficacy of TIL
therapy can be enhanced by the preparation of more defined tumor-reactive T cell products.
Introduction
Immunotherapeutic treatment of melanoma has seen major
progress in recent years. As a first example, following work in
mouse model systems that demonstrated that antibody-mediated
blockade of T cell checkpoint molecules could be used to enhance
tumor-specific T cell responses,
1 a number of such antibodies have
been evaluated in clinical trials. Antibody-mediated blockade of
the PD-1/PD-L1 axis has shown promise in early phase clinical
trials.
2 More importantly, a recent randomized Phase III trial has
demonstrated a survival benefit of anti-CTLA4 treatment in
patients with metastatic disease.
3 In patients that experience a
clinical benefit of anti-CTLA4 treatment, an increase in blood
CD8
+ T-cell counts has been observed.
4 Likewise, an increase in
CD8
+ T-cell frequencies has been observed in tumor lesions that
regress upon anti-CTLA4 treatment.
5
As a second strategy to enhance melanoma-specific T-cell
reactivity, Stage IV melanoma patients have been treated by
infusion of large numbers of ex vivo expanded tumor-infiltrating
T cells (TIL). TIL therapy has led to a 50% RECIST response
rate in clinical trials in 2 centers.
6,7 Although unfractionated TIL
products used for therapy generally contain both CD4
+ and CD8
+
T cells, cell therapy with CD8-enriched TIL products has also
been shown to lead to clinical responses.
8
Based on the above data it is reasonable to speculate that cancer
regression upon T cell checkpoint blockade or TIL therapy is at
least in part mediated by the activity of cytotoxic CD8
+ T cells.
However, our knowledge of the CD8
+ T cell reactivity that is
induced by either therapy is highly limited. This lack of
information can be explained by a combination of two factors.
First, the number of shared melanoma-associated epitopes to
which CD8
+ T-cell responses have been described is in the order
of hundreds. Second, the amount of clinical material required for
classical strategies for tumor-specific CD8
+ T-cell monitoring only
allow one to evaluate T-cell reactivity against at most a few of
these epitopes.
To understand how immunotherapy of cancer influences the
patterns of tumor-specific CD8
+ T-cell reactivity we developed a
platform that can be used to profile T cell responses against the
full panel of known melanoma-associated CD8
+ T cell epitopes.
We have used this T-cell profiling platform to evaluate
melanoma-specific CD8
+ T-cell reactivity in patients treated with
TIL therapy, focusing on three main questions: (1) Which antigen
classes are predominantly recognized by CD8
+ T cells in TIL
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products? (2) Does TIL therapy increase the magnitude or
breadth of the melanoma-specific CD8
+ T cell response? (3) Is
there evidence for epitope spreading upon TIL therapy, or is
T-cell reactivity post-therapy restricted to the T-cell reactivity
that is infused? The data obtained demonstrate how CD8
+ T-cell
profiling can be used to reveal how immunotherapeutic strategies
influence T-cell reactivity upon cancer treatment and suggest
avenues for the further development of TIL therapy for human
melanoma.
Results
Profiling of antigen-specific CD8
+ T-cell responses in mela-
noma. To allow the analysis of therapy-induced CD8
+ T cell
reactivity against any of the known shared melanoma-associated
epitopes we compiled a list of all previously described HLA class
I-associated epitopes (Andersen RS et al., manuscript submitted).
Of the 215 melanoma-associated epitopes identified, a large
majority (145) was restricted to the HLA-A2 allele, and for this
reason we focused our analysis of TIL-therapy-induced T-cell
reactivity on this allele. This set of 145 HLA-A2 restricted
epitopes (Table S1) is composed of three major subgroups:
melanocyte differentiation (MD) antigens such as MART-1/
Melan A (18%), cancer/testis (CT) antigens such as the MAGE
family and NY-ESO 1 (27%), and a large group of overexpressed
(OE) antigens, such as Meloe-1 and survivin (45%). Using UV-
induced peptide exchange, a high-throughput technology for
MHC multimer generation,
9 we generated HLA-A2 multimers
for all 145 melanoma-associated epitopes. Each peptide-HLA
multimer was then conjugated to 2 out of 8 fluorescent dyes to
create two-color codes. Subsequently, panels that each contain
peptide-MHC multimers for 25 different epitopes were prepared
for T cell staining, such that every pMHC multimer within the
panel was encoded by a unique two-color code
10 (Fig.S1).
Melanoma-specific CD8
+ T-cell populations in TIL infusion
products. To assess which melanoma-specific CD8
+ T-cell
reactivities are present within TIL products used for therapy, we
analyzed 22 HLA-A2
+ “young TIL”
11 that were produced by in
vitro expansion of T cells from resected tumor material (16 NIH
TIL products, 6 Ella TIL products). Specifically, cell samples from
each TIL infusion product were stained with the panel comprising
the 145 melanoma-HLA-A2 pMHC multimers, and hits were
identified using standardized cut-off (see Methods). All hits were
subsequently validated in an independent experiment, examples
are shown in Figure1A.
This screen resulted in the identification of 60 melanoma
antigen-reactive T-cell populations that targeted 19 different
epitopes (Fig.1B). Notably, while these T-cell products were
expanded from tumor-infiltrating lymphocytes, the magnitude of
the HLA-A2-restricted T-cell responses that were detected was
strikingly low (median magnitude of individual epitope-specific
T-cell responses: 0.12% of CD8
+ T-cells, range 0.006–4.5%;
median combined magnitude of HLA-A2-restricted T-cell
responses per patient product: 0.59% of CD8
+ cells, range 0–
4.75%). Even taking into account that HLA-A2 forms only one
out of six HLA class I alleles that can be expressed by an
individual patient, these data indicate that the frequency of T cells
specific for shared melanoma antigens that is detected in “young
TIL” is very low.
Antigen-specific T-cell populations exist at low frequencies.
Clinical trials of TIL therapy have both been performed with
“young TIL” cell products and with “selected TIL” cell products.
In the latter case, TIL cultures that produce IFNc upon
incubation with autologous or partially HLA-matched melanoma
are selected from a series of parallel cultures. While this ELISA-
based screening system establishes that tumor-reactive T cells are
present within these cultures, the magnitude of these responses is
not revealed. To determine whether the selection for tumor-
reactive TIL or the extended in vitro culture that is required to
produce these “selected TIL” could yield cell products with
enhanced frequencies of T cells reactive against shared melanoma-
associated antigens, we screened a total of 12 HLA-A2
+ “selected
TIL” samples (9 NIH/3 Ella institute). Notably, also in these cell
products, T cells reactive with shared HLA-A2-restricted antigens
made up a surprisingly small fraction of the total CD8
+ T-cell
pool (median 0.159%, range 0.006–10.295% of CD8
+ cells;
Fig.2).
To address whether the low level T-cell responses detected in
TIL reflected true antigen-driven T-cell expansion, for a small set
of antigens we assessed whether the presence of an antigen-specific
T-cell response correlated with the expression of the respective
antigen in fresh tumor tissue from the same patient. Comparison
of these two independently generated data sets indicated that
T-cell reactivity and antigen expression were strongly correlated
(30 out of 32 comparisons matched, Fig.3A). Second, for 4 TIL
(3 pre-REP TIL, one infusion product), we evaluated which
proportion of reactivity against autologous tumor can be
attributed to T-cell populations detected by MHC multimer
staining. On average, T-cell reactivity as measured by MHC
multimer staining corresponded to approximately one-sixth
(18%) of that detected by functional screening (Fig.3B).
Although the IFNc-based assay can obviously only reveal
functionally active cells, this ratio fits well with the fact that in
the former case reactivity is only measured for one out of six
possible HLA alleles. As a final validation of our assay system, we
analyzed the cell product from a tumor lesion of a patient that
had previously been treated by infusion of MART-1 TCR-
modified T cells.
12 Notably, in this TIL cell product a very
prominent (. 80% of CD8
+ T cells) MART-1-reactive T-cell
population was detected (Fig.3C). Thus, in a case in which a
high magnitude tumor-reactive T cell response is present, such a
response is readily detected.
To address whether TIL cell products also contain T-cell
populations specific for non-melanoma antigens, we analyzed 13
TIL products for the presence of T cells reactive with a panel of
eight epitopes from common human pathogens (CMV, EBV,
influenza A). Interestingly, reactivity against viral epitopes was
detected in 6 out of 13 TIL products screened, although the
magnitude of these virus-specific T cell responses (average 0.036,
n = 13) was below that seen in peripheral blood in those cases in
which matched samples were available (average 0.87, n = 4)
(Fig.3D). In conclusion, both young and selected TIL products
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contain relatively low frequencies of T cells that are reactive with
shared HLA-A2 restricted melanoma-associated antigens and TIL
infusion products do contain T cells that are reactive with non-
melanoma antigens.
When comparing the relative contribution of T cell responses
against the MD, CT and OE antigens, it is apparent that reactivity
patterns against these antigen classes are different. Specifically,
withinthe34TILinfusion productsanalyzed, reactivity againstOE
antigens is found against less than 10% of the epitopes that have
been described within this antigen class. Interestingly, four out of
five OE epitopes against which reactivity is observed are derived
from cryptic open reading frames or alternative splicing events,
suggesting that T-cell recognition is mostly observed for those OE
epitopesforwhichthymictolerancecanbeexpected tobeless strict.
The percentage of CT antigen-derived epitopes to which T cell
responses are observed is higher (22.5%). This CT reactivity is
diverse rather than being dominated by the frequent recognition of
the same epitopes, as shown by the fact that the number of T cell
responses goes up in an almost linear fashion with the number of
patients screened (Fig.S2). Reactivityagainst themelanocytediffer-
entiation antigens is observed against an even higher percentage of
the epitopes within this class, but in this case, reactivity against
Figure1. Melanoma-specific CD8
+ T cell reactivities within TIL infusion products. (A) Examples of flow cytometry plots displaying fluorescence intensity
for Meloe-1TLN, MART-1ELA, SSX-2KAS and MAGE A10GLY pMHC multimer-reactive cells in TIL samples from two patients. Dot plots were gated on
approximately 500,000 CD8
+ lymphocytes. Grey dots represent CD8
+ T cells with no pMHC multimer binding, blue dots represent pMHC multimer–
reactive CD8
+ T cells. Plots are shown with bi-exponential axes. Values indicate the % of antigen-specific T cells out of total CD8
+ T cells. (B) Summary of
antigen-specific T-cell populations identified in HLA-A2
+ NIH and Ella TIL infusion products. The presence of antigen-specific T cell populations is
indicated by the colored boxes, with the different colors reflecting antigen-specific CD8
+ T-cell response magnitude. Only those epitopes are shown for
which T-cell reactivity was detected in at least one patient sample. Patient numbers on top row, clinical responses on bottom row. PR, partial response;
NR, no response.
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more frequent than that against others (Fig.4; Fig.S2).
Finally, in one TIL product that was prepared for research
purposes, we identified a T-cell response against a mutated
epitope of CDK4 (CDK4ACD; Fig.3E and F), and the presence
of a CDK4R24L mutation in the tumor (but not lymphocytes) of
this patient could subsequently be demonstrated. The magnitude
of this mutant CDK4-specific T-cell response (0.68% of CD8
+
cells) was in the same range as that observed for non-mutated
antigens, indicating that the magnitude of T-cell responses that
are directed against neo-antigens can also be low.
Melanoma-specific T-cell reactivity identified in TIL products
predicts T-cell reactivity post-therapy. Having analyzed the
composition of TIL products used for infusion, we determined
whether TIL therapy alters the tumor-reactive T-cell repertoire in
melanoma patients. To this purpose we profiled antigen-specific
T-cell reactivity in one-month post-infusion PBMC samples
from 10 NIH patients and 9 Ella patients. Within these 19 post-
infusion PBMC samples a total of 32 antigen-specific T-cell
populations targeting 13 distinct epitopes were identified
(Fig.5A). Comparison of the T-cell responses in the matched
TIL products indicated that a large fraction of the T-cell responses
that was infused was also encountered in post-infusion PBMC (31
out of 56, 55%), and likelihood of engraftment was correlated
with the magnitude of the TIL T-cell response (data not shown).
Importantly, nearly all (31 of 32, 97%) of the melanoma-reactive
T-cell responses that were observed in post-therapy PBMC were
also detected in the TIL product that was used for infusion.
To evaluate whether this close link between T-cell reactivity in
infusion products and post-infusion PBMC reflected the effect of
TIL therapy, or simply reflected the presence of pre-existing
peripheral blood T-cell responses against these antigens we
analyzed pre-therapy PBMC samples from seven patients for
whom material was available. In these pre-treatment PMBC
samples only two melanoma-specific T-cell responses could be
detected in total, whereas the matched TIL product and post-
therapy PBMC samples contained 20 and 16 detectable T-cell
responses, respectively (Fig.5B). These data indicate that TIL
therapy results in a substantial broadening of the detectable tumor-
specific CD8
+ T-cell response in melanoma patients (p = 0.006).
To examine the role of stochastic processes in determining the
reactivities observed in TIL cultures, we generated enzymatic
digests from tumors of two patients. Subsequently, six TIL
cultures of each tumor digest were prepared in parallel. After two
weeks of culture, individual TIL cultures were screened using the
145 epitope panel. Even though these TIL cultures were derived
from the same starting cell population, the composition of
individual TIL cultures varied substantially (Fig.6A–B; Fig.S3).
For instance, T-cell populations reactive against MAGE-C2LLF in
patient NKI1 were either among the strongest detected or were
below the level of detection. In patient NKI2, a MART-1ELA
specific T-cell response was detected in all six cultures but at
frequencies that varied over 100-fold. These data indicate that
even a stochastic variation between TIL cultures prepared from
the same starting material can lead to marked variation in the
T-cell reactivity that emerges.
Discussion
Despite the fact that cytotoxic T-cell activity is considered to be
responsible for at least part of the clinical effects of recently
developed cancer immunotherapies, our knowledge of therapy-
induced CD8
+ T-cell activity is still very modest. Here we have
utilized a strategy for antigen-specific CD8
+ T-cell profiling to
dissect melanoma-specific T-cell reactivity in TIL therapy. Even
though analysis was performed for only a single HLA allele,
melanoma-specific CD8
+ T-cell responses were observed in 30 out
of 34 TIL products that were analyzed, and in most TIL products
this involved reactivity against multiple epitopes. These data
demonstrate that the recognition of shared melanoma antigens by
TIL products is a very frequent event. Nevertheless, the most
striking finding of our analyses is the relatively low magnitude of
the T-cell responses against this panel of 145 epitopes. Only a
minor fraction of the antigen-specific T-cell responses detected
exceeded 1% of CD8
+ T cells and in fact in most TIL products
the combined magnitude of T-cell reactivity against these 145
epitopes explained less than 1% of CD8
+ TIL. For those TIL
products/ antigens for which this was analyzed, the presence of
T-cell reactivity correlated tightly with antigen expression,
underlining the reliability of our T-cell assays even for low-level
responses. As T-cell reactivity against the large panel of known
shared melanoma-associated antigens explains only a small
fraction of CD8
+ TIL, what is the antigen reactivity of the
remaining cells? First, our data demonstrate that TIL do contain
Figure2. Selection for tumor-reactive TIL does not lead to enhanced
frequencies of shared melanoma-antigen reactive CD8
+ T cells. Summary
of antigen-specific T cell populations identified in HLA-A2
+ NIH and Ella
“selected TIL” infusion products. TIL were selected on the basis of IFNc
production in the supernatant upon culturing with autologous or shared
melanoma lines. The presence of antigen-specific T-cell populations is
indicated by the colored boxes, with the different colors reflecting
antigen-specific CD8
+ T cell response magnitude (see Figure1B for key).
Only those epitopes are shown for which T cell reactivity was detected in
at least one patient sample. Clinical responses are summarized in the last
row. CR, complete response; PR, partial response; NR, no response.
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T cells that are reactive against non-melanoma antigens, as shown
by the presence of T-cells specific for EBV, influenza and CMV
antigens. Second, TIL can contain T cells reactive against neo-
antigens, as shown by the presence of CDK4R24L-specific T cells
in the TIL of a patient with a CDK4-mutant melanoma. At
present the relative contribution of these two types of reactivity
has not been established. However, if the number of neo-antigens
per HLA allele is around 7–10, as based on prior predictions,
13
individual neo-antigen-specific T-cell responses would have to be
of a much larger magnitude than the shared antigen-specific T-cell
Figure3. Validation of low-frequency T-cell populations detected in TIL. (A) MART-1, gp100, MAGE A10, SSX-2 expression by fresh tumor cells was
measured by quantitative RT-PCR and correlated with the antigen-reactivities detected in matched TIL. Dark blue: tumor cells express the antigen and
antigen-specific T cell population detected in the TIL infusion product. Light blue: tumor cells express the antigen, but no antigen-specific T cell
population detected in the TIL infusion product. Red: tumor cells do not express the antigen, but antigen-specific T-cell population detected in the TIL
infusion product. White: tumor cells do not express the antigen and antigen-specific T-cell population not detected in the TIL infusion product. (B)
Intracellular IFNc staining assay after co-culture of TIL with autologous melanoma cell lines (left axis) in comparison with the total frequency of CD8
+
pMHC multimer
+ identified (right axis). (C) Dot plot of MART-1ELA specific T-cell population in TIL of a recipient of MART-1 TCR-modified T cells. Value
indicates the percentage of antigen-specific T cells out of total CD8
+ T cells. (D) Summary of virus-specific T cell populations identified in six HLA-A2
+ NIH
and Ella TIL infusion products (see Figure1B for key). (E) Dot plot of CDK4ACD-specific T-cell population detected in TIL. Value indicates the percentage of
antigen-specific T cells out of total CD8
+ T cells. (F) Intracellular IFNc staining assay performed with FACS-sorted CDK4ACD-reactive T cells, with the cells
being incubated either with T2 cells pulsed with or without the CDK4ACD peptide or an autologous tumor line (HLA-A2
+). Melanoma cell lines 526 (HLA-
A2
+, CDK4R24C), 624 (HLA-A2
+, CDK4WT), and 888 and 938 (HLA-A2
-) were used as controls.
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responses studied here to collectively make up a large part of the
TIL T-cell population.
The patterns of T-cell reactivity that were observed for the
three major classes of shared melanoma antigens varied substanti-
ally. Reactivity against overexpressed antigens was rare, in parti-
cular when taking into account that this antigen class comprises a
substantial fraction of the T cell epitopes that have been described
for melanoma. On the contrary, consistent with prior data on T
cell reactivity in melanoma,
14,15 reactivity against the melanocyte
differentiation antigen MART-1 was very common, and reactivity
against multiple gp100 epitopes was also frequently observed.
However, the presence of MART-1 or gp100-specific T cell res-
ponses did not correlate with a favorable clinical outcome, and
in this cohort, reactivity against MD antigens made up a slightly
larger fraction of the T cell responses detected in non-
responding patients (77.5%) than in patients that showed
cancer regression upon TIL infusion (64.4%) (Fig.4C and
D). CD8
+ T-cell responses against CT antigens, the third
major class of antigens, were substantially less common than
T-cell responses against MD antigens. Interestingly though,
there was a trend (p = 0.12, n.s.) toward the preferential
detection of T-cell responses against CT antigens in patients
that showed a clinical response to TIL therapy (six of eight
patients with CT reactivity vs. 10 of 26 without CT reactivity).
By the same token, reactivity against CT antigens made up a
larger fraction of the T-cell responses detected in responding
(20%)thaninnon-respondingpatients(7.5%). Thehypothesis
that recognition of CT antigens may be associated with a
favorable clinical outcome upon TIL therapy is consistent with
the clinical responses of recipients of NY-ESO TCR-modified
T cells,
16 but analysis of a larger cohort of TIL-treated
patients will obviously be essential to test this hypothesis.
To address whether TIL therapy influences the melanoma-
specific CD8
+ T-cell repertoire and to what extent such an
effect could be predicted by the composition of the TIL
product we compared CD8
+ T-cell responses against the 145
epitope set in pre-treatment PBMC, the TIL product, and
post-treatment PBMC. From the comparison of pre- and
post-treatment PBMC it is evident that TIL therapy leads to a
substantial broadening of the detectable melanoma-specific
CD8
+ T-cell repertoire (p = 0.006). Importantly, virtually all
the CD8
+ T-cell responses that were observed at 1 mo post-
therapy were already detectable within the matched infusion
product. This indicates that within this timeframe, no
detectable new T-cell responses arise from either systemic T
cells that survived the conditioning regimen, or from low
frequency T cells contained within the ~10
10 T cells infused.
Thus, the epitope spreading for which there is evidence in
some vaccination studies
17,18 does not play a detectable role
in TIL therapy: T-cell reactivity at 1 mo post-therapy—
when tumor regression is often already clinically evident—is
determined by the composition of the cell product.
What do the current data mean for the further develop-
ment of TIL therapy? The observation that all the antigen-
specific T-cell responses that are detected in TIL infusion
products are low-level, including those T-cell responses that
are directed against antigens for which tolerance is presumed to be
less stringent (CT antigens) or non-existent (mutant CDK4) is
unexpected and at first glance disappointing. The fact that these
responses are of such a low magnitude however opens the
possibility that strategies to steer T-cell reactivity to some of these
antigens could further increase the efficacy of TIL therapy.
Specifically, as melanoma-specific T-cell reactivity post-therapy is
essentially fully explained by the composition of the cell product,
the use of T-cell populations that are enriched for reactivity
against one or multiple antigens of interest, either by MHC
multimer enrichment
19,20 or cytokine capture
21,22 is likely to lead
to a more profound reactivity against these antigens post-therapy.
Based on the current data, infusion of T cells enriched for
reactivity against CT antigens could be considered. Furthermore,
Figure4. Contribution of antigen classes to T cell reactivity in TIL.
(A) Contribution of the indicated antigen classes to the epitope panel.
MD, melanoma differentiation antigens; CT, cancer/testis antigens; OE,
overexpressed antigens; unclassified, antigens that cannot be designated to a
specific class based on available data; mutated, mutated antigens.
(B) Contribution of antigen classes to the antigen-reactive T-cell populations
detected in both non-selected and selected TIL infusion products.
(C and D) Contribution of antigen classes to the antigen-reactive T-cell
populations detected in TIL infusion samples from clinical non-responders
(C) and responders (D). The numbers in the center of the pie charts represent
the total number of T-cell responses detected. The numbers within the
individual pie sections indicate the percentage of T-cell responses in each
category of all T-cell responses detected.
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with the development of technology to evaluate the patient-
specific repertoire of mutated epitopes
23,24 it may well become
possible to expand such a selection to T-cell populations that are
reactive against patient-specific neo-antigens.
Finally, while we here have used CD8
+ T-cell profiling to
evaluate the effects of TIL therapy, the technology should also
be useful to address a series of other issues. Ongoing experi-
ments suggest that it will be feasible to address to what extent
Ipilimumab treatment
3 influences T-cell reactivity against the
shared melanoma antigens in melanoma patients and to what
extent this correlates with clinical course. As a second example,
the targeting of mutant B-RAF by Vemurafenib has shown a very
high response rate in patients with metastatic melanoma,
25 and
the combination of anti-CTLA4 treatment and B-RAF inhibition
forms a logical next step. It will be of interest to determine to
what extent tumor cell death induced by B-RAF inhibition can
by itself enhance melanoma-specific T cell responses, or whether
B-RAF inhibition can enhance the effects of anti-CTLA4
treatment on the tumor-specific T-cell repertoire in melanoma.
Materials and Methods
Generation of pMHC complexes. Melanoma-associated peptides
were purchased from Pepscan (Pepscan Presto BV) and UV
Figure5. Melanoma-specific T cell reactivity identified in TIL products predicts T-cell reactivity post-therapy. (A) Summary of antigen-specific T-cell
populations identified in one-month post-infusion PBMC samples (post) from NIH and Ella patients depicted together with the T-cell reactivities
identified in the matched TIL infusion product (infusion). The presence of antigen-specific T-cell populations is indicated by the colored boxes, with the
different colors reflecting antigen-specific CD8
+ T-cell response magnitude. Only those epitopes are shown for which T-cell reactivity was detected in at
least one patient sample. Patient numbers on top row, clinical responses on bottom row. CR, complete response; PR, partial response; NR, no response.
(B) Relationship between melanoma-specific T-cell responses (% of total CD8
+ T cells) detected in pre-therapy PBMC (pre), TIL infusion samples, and
post-infusion PBMC (post) from seven NIH patients. Each square represents an antigen-specific T-cell population, each color represents T-cell responses
detected within one patient (* p , 0.05)
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cleavable peptides were synthesized in-house as described
previously.
9 Recombinant HLA-A2 heavy chains and human
β2 m light chain were produced in Escherichia coli and isolated
from inclusion bodies. MHC class I refolding reactions and
purification by gel-filtration HPLC was performed as described
previously.
26 Specific peptide-MHC complexes were generated by
UV-induced ligand exchange
9 in a 96 well format. In brief,
pMHC complexes loaded with UV-sensitive peptide (100 mg
ml
21) were subjected to 366 nm UV light (Camag) for 1 h at 4°C
in the presence of rescue peptides (200 mM).
10
Generation of pMHC multimers. pMHC multimers were
generated using a total of eight different fluorescent streptavidin
(SA) conjugates (Invitrogen). For each 10 ml of pMHC monomer
(100 mgm l
21), the following amount of SA-conjugates was
added: 1.5 ml SA-QD605 (Q10101MP), 1.0 ml SA-QD625
(A10196), 1.5 ml SA-QD655 (Q10121MP), 1.5 ml SA-QD705
(Q10161MP), 1.0 ml SA-QD800 (Q10171MP), 1.1 ml SA-PE
(1 mg ml
21, SA1004–4), 1.1 ml SA-PE-Cy7 (1 mg ml
21, SA1012)
and 0.6 ml SA-APC (1 mg ml
21, SA1005). For each pMHC
monomer, conjugation was performed with two of these fluo-
rochromes, as detailed in FigureS1. Mixtures were incubated
30 min on ice. NaN3 (0.02% wt/vol) was added and an excess of
D-biotin (26.4 mM, Sigma) was added to block residual binding
sites.
Cells and T cell staining. TIL infusion products and PBMC
samples were obtained from individuals with Stage IV melanoma
in accordance with local guidelines, with informed consent. The
median number of CD8
+ cells infused was 31.7  10
9 (range
0.72–55.8  10
9) for 15 products for which data was available.
Pre-treatment PBMC samples were collected with a median of
36 d (standard deviation 66 d) prior to TIL infusion. Post-
treatment PBMC samples were collected 27 d (median, standard
deviation 3 d) subsequent to TIL infusion. All samples were
cryopreserved in FCS with 10% DMSO and stored in liquid N2
before shipment to NKI. Samples were shipped on dried ice
from NIH and Ella institute, and again stored in liquid N2 until
used. Cells were thawed on the day of analysis and cell numbers
were determined using trypan blue to exclude dead cells.
For T cell staining, the following amounts of fluorescently
labeled pMHC complexes were pooled together for combinatorial
coding, or used separately for confirmations: 1 ml of PE-pMHC,
2 ml of APC-pMHC, 3 ml of QD605-pMHC, 2 ml of QD625-
pMHC, 2 ml of QD655-pMHC, 4 ml of QD705-pMHC, 4 ml
of QD800-pMHC, 3 ml of PE-Cy7-pMHC. Final staining
volume was 128 ml and cells were incubated at 37°C for 15 min.
For combinatorial coding on PBMCs, 2 ml anti-CD8-FITC
(BD 345772), 1 ml anti-CD4-AF700 (Invitrogen MHCD0429),
1 ml anti-CD14-AF700 (Invitrogen MHCD1429), 1 ml anti-
CD16-AF700 (Invitrogen MHCD1629), 3 ml anti-CD19-
AF700 (Invitrogen MHCD1929) and 0.5 ml LIVE⁄DEAD
1
Fixable IR Dead Cell Stain Kit (invitrogen L10119) was then
added. Antibody stainings were followed by incubation on ice for
30 min. Before flow cytometry analysis, cells were washed twice.
Flow cytometry. Data acquisition was performed on a LSR-II
flow cytometer (Becton Dickinson) with FacsDiva software. The
following 11 color instrument setting was used for combinatorial
coding analyses: UV laser (355 nm): QD605, 595LP, 605/12;
QD705, 685LP, 710/50; QD800, 750LP, 780/60. Violet laser
(405 nm): QD625, 610LP, 625/20; QD655, 635LP, 655/8. Blue
laser (488 nm): FITC, 505LP, 525/50. Yellow-green laser
(561 nm): PE, 585/15; PE-Cy7, 750LP, 780/60. Red laser
(640 nm): APC, 670/14; AF700, 685LP, 710/50; IR-Dye,
750LP, 780/60. To identify antigen-specific T cells, the following
gating strategy was used. (1) Selection of live (IR-dye negative)
single cell lymphocytes (FSC-W/H low, SSC-W/H low, FSC/
SSC-A). (2) Selection of anti-CD8-FITC
+ and “dump” (anti-
CD4, -CD14, -CD16, -CD19) negative cells. (3) Selection of
CD8
+ T cells that were positive in two and only two MHC
multimer channels. Cut off values for the definition of positive
responses were $ 0.005% of total CD8
+ cells and $ 10 events.
500,000 CD8
+ T cells were recorded per sample when possible
and a minimum of 50.000 CD8
+ T cells was acquired.
IFNy release assay. To address reactivity of mutant CDK4
epitope-specific T cells, tetramer-positive were sorted and cultured
as described previously.
10 T2 cells were loaded with the indicated
peptides for 1 h and washed once. Subsequently, 1  10
5 T cells
(79.5% MHC-multimer
+) were incubated with 1  10
5 T2 cells
for 4 h at 37°C in RPMI with 10% human serum and protein
transport inhibitor (BD GolgiPlug, 555029). Cells were stained
with PerCP-Cy5.5-conjugated anti-CD8 (BD, 341051) for
20 min at 4°C, fixed and permeabilized (BD Cytofix/Cytoperm
kit, 555028), and stained with APC-conjugated anti-IFNc (BD,
340452) for 30 min at 4°C. Samples were analyzed by flow
cytometry (Calibur, Becton Dickinson), data analysis was
performed using FlowJo software.
Figure6. Random variability in TIL composition during in vitro culture.
Magnitude of antigen-specific T-cell populations (percent of total CD8
+ T
cells) in six different T-cell cultures originating from the same tumor
digest of (A) patient NKI1 and (B) patient NKI2. T-cell cultures were
initiated in separate wells (1–6) and cultured for approximately 2 weeks
prior to analysis of T-cell reactivity.
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To address reactivity of TIL against autologous tumor cell lines,
TIL cultures (1  10
5, pre-rapid expansion cultures for the NKI
samples and TIL infusion product for the TIL sample from Ella
Institute) were incubated with 1  10
5 autologous tumor cells for
4 h at 37°C in RPMI with 10% human serum and protein
transport inhibitor (BD GolgiPlug, 555029). Staining and
analysis of the cells were conducted as described above.
Tumor antigen analysis. Total RNA was isolated using the
RNeasy Mini Kit (Qiagen, 74104). First strand cDNA was
generated from 0.5 mg total RNA using the ThermoScript RT-
PCR System (Invitrogen, Inc., 11146-016). Quantitative RT-
PCR assays analyzing tumor antigen gene expression were
performed for 40 cycles with an annealing temperature of 60°C
using TaqMan Gene Expression Assays (Applied Biosystems, Inc.)
and were normalized using GAPDH.
Statistical analyses. The difference in the number of T-cell
responses in pre- and post-treatment PBMC samples was assessed
by two-tailed, paired Student’s t-test. The correlation between
clinical outcome and the presence of CT specific T-cell reactivities
in TIL products was assessed by Fisher’s exact test.
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